They have 322 million in the bank right now. they have dozens of partners who are paying something for the antibody services. they were profitable last quarter. yet they are diluting their stock and raising more cash to keep building.
AVN has 20 million in the bank. if it is squeezing out 12 targets per quarter on its budget, that's pretty good management. but it's still small time. Now if they divest 20-25% of Xenerex for 200 million dollars or more, you would see a huge sustainable move in the stock price. no diluting of AVN's stock, and no spin-off necessary at this point.
if you want a big time company, it has to make bold big time moves. just my armchair quarterback opinion after observing none of the touted accomplishments having much of an effect on the stock price.
it looks like MEDX is doing everything it can to insure its success and to play with the big boys. its like a poker game, you need lots of chips to play in the BIG game. meanwhile AVN is still in the penny ante game. they need to do something to raise cash if they want to play in the big game and become a force in bio-tech the way MEDX has become.